Douglas Foerster
Senior Vice President, Pricing & Market Access
Expertise:
Douglas leads EVERSANA’s pricing and market access team to strategically drive new drugs to the global market. A proven European Market Access launch readiness and commmercialisation expert with 15 years in healthcare, health economics and the pharmaceutical industry, Douglas has extensive experience across a range of therapeutic areas, including neurology, infectious diseases, nephrology, vaccines and rare diseases. Prior to joining EVERSANA, Douglas held leadership roles in established and emerging pharmaceutical organizations and recently was Head of Market Access EU and Rest-of-World for Santhera Pharmaceuticals where he prepared the European launch for the Duchenne muscular dystrophy portfolio. Prior, he led European market access strategies for neuroscience products at Lupin and worked for Vifor, Cubist, Novartis Vaccines and Abbvie/Abbott. Throughout his career, he has led market access and pricing activities for drug launches at the global and local levels.
Douglas is an active member of the International Society of Pharmacoeconomics and Outcome Research, International Health Economic Association, and Deutsche Gesellschaft für Gesundheitsökonomie (The German Health Economic Association). He holds a master’s degree in economics from University Heidelberg, Germany.
Articles by Douglas Foerster
What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)
Facing the “Fourth Hurdle” Member states of the European Union benefit from a centralised marketing authorisation process for medicinal products. Also, since its implementation in 1993, the European Medicines Agency (EMA) has assured pharmaceutical companies the right to commercialise products that underwent a centralised marketing authorisation in the second largest (and most diverse) single pharma market. However, it remains “the responsibilities of the Member States [to define] their health policy and for the organisation and delivery of health services and medical care. The responsibilities of the Member States shall include the management of health services and medical care and the allocation of the resources assigned to them” (Art. 168, “Treaty […]
EPP Studio Live Webinar — Impact of COVID-19 Pandemic on German Healthcare System
Leading up to the recent German elections, the topic of healthcare took center stage for the aging German population. With nearly 90% of the population participating in Statutory Health Insurance (SHI), increased financial pressures have widened the gap between SHI coverage and anticipated expenditures. During this EPP Studio Live Webinar, Douglas Foerster, Senior Vice President of Pricing & Market Access for EVERSANA, and Mathias Flume, Head of Drug Development for KVWL, discuss how various political parties are responding to these challenges and the potential impact on market access and pricing in Germany. WATCH NOW:
EPP Studio Live Webinar — EU Joint Procurement of COVID-19 Vaccines: A Model for Future Market Access in Europe?
The COVID-19 pandemic has changed the way we live and the way we respond to global healthcare crises. During this EPP Studio Live webinar, Douglas Foerster, Senior Vice President of Pricing & Market Access for EVERSANA, shares a brief historical summary of how the European Union negotiated the acquisition of COVID-19 vaccines through an unprecedented, and somewhat controversial, joint procurement process. Mr. Foerster and Professor York Zöllner of the Hamburg University of Applied Sciences discuss the pros and cons of this joint procurement approach as they explore various scenarios under which this process may offer future market access considerations of cost, speed, efficiency and equity. WATCH NOW: